Cannabis Science
Confirms Receipt of Issued US Patent Number 9,763,991 For
Compositions of Cannabinol (CBN) for Treatment of Various
Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety
Disorders (ADHD), and Post-Traumatic Stress Disorders
(PTSD)
IRVINE,
CA --
October
29, 2018 -- InvestorsHub
NewsWire
--
Cannabis Science, Inc. (OTC:
CBIS),
a U.S. company specializing in the development of cannabinoid-based
medicines, is pleased to confirm receipt of Issued US Patent
Number 9,763,991 For Compositions of Cannabinol (CBN) for Treatment
of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia),
Anxiety Disorders (ADHD), and Post-Traumatic Stress Disorders
(PTSD) among other target indications.
The invention relates
to a composition for use in the treatment of neurobehavioral
disorders utilizing various Cannabis plant extracts comprising
Cannabinol (CBN) preferably with other constituents of this plant
for such use and a method for the extraction of plants. The plants
or plant parts may for instance be derived from Cannabis Sativa
and/or Cannabis Indica and/or Cannabis ruderalis and/or other
elements, and mixtures thereof. The plant extracts derived showed
particularly beneficial effects against Sleeping Disorders, in
particular Insomnia, Post-Traumatic Stress Disorder (PTSD), and
anxiety disorders including Attention Deficit Hyperactivity
Disorder (ADHD).
"PTSD is becoming one
of the most international wide-spread pandemic conditions, in the
Military it seems to be causing a chain reaction, in families it
seems to be causing mass confusion to the triggers, in children it
is a mystery staring us right in the face. Internationally, PTSD is
one of the main reasons insomnia and ADHD has spread
prolifically.
In U.S.A. alone,
statistic has shown that there are over 50 million people with
chronic sleep disorders, plus 20 million people with occasional
sleep disorders.
Most of
these people use some form of prescription drugs or Melatonin to
help their sleep disorders.
However,
some common FDA approved treatments and drugs have advertised side
effects, such as daytime drowsiness, depressed mood, feeling
irritable, stomach pain, headache, dizziness, breast enlargement in
men, decreased sperm count in men, etc... There
is definitely a sufficient number of people with demand to help
their sleep disorders without the side effects of these other types
of harmful solutions.
From the United
States a Direct Quote from the NIH:
PTSD
is a disorder that develops in some people who have experienced a
shocking, scary, or dangerous event.
It is
natural to feel afraid during and after a traumatic situation. Fear
triggers many split-second changes in the body to help defend
against danger or to avoid it. This "fight-or-flight" response is a
typical reaction meant to protect a person from harm. Nearly
everyone will experience a range of reactions after trauma, yet
most people recover from initial symptoms naturally. Those who
continue to experience problems may be diagnosed with PTSD. People
who have PTSD may feel stressed or frightened even when they are
not in danger.
Please
click this link to read the full report:
https://www.nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd/index.shtml
From Canada a Direct quote from the CDMA:
Frightening situations happen to everyone at some point. People can
react in many different ways: they might feel nervous, have a hard
time sleeping well, or go over the details of the situation in
their mind. These thoughts or experiences are a normal reaction.
They usually decrease over time and the people involved can go back
to their daily lives. Post-traumatic stress disorder, on the other
hand, lasts much longer and can seriously disrupt a person's
life.
Post-traumatic stress
disorder (PTSD) is a mental illness. It involves exposure to trauma
involving death or the threat of death, serious injury, or sexual
violence.
Something
is traumatic when it is very frightening, overwhelming and causes a
lot of distress. Trauma is often unexpected, and many people say
that they felt powerless to stop or change the event. Traumatic
events may include crimes, natural disasters, accidents, war or
conflict, or other threats to life. It could be an event or
situation that you experience yourself or something that happens to
others, including loved ones.
PTSD
causes intrusive symptoms such as re-experiencing the traumatic
event. Many people have vivid nightmares, flashbacks, or thoughts
of the event that seem to come from nowhere. They often avoid
things that remind them of the eventfor example, someone who was
hurt in a car crash might avoid driving.
Please
click this link to read the full Report:
https://cmha.ca/documents/post-traumatic-stress-disorder-ptsd
Cannabis
Science will immediately go into commercial production in various
markets depending on regulatory environment and approvals. The
Company is making various supplement combinations with CBN
targeting Sleep Disorder and PTSD. The Company will aggressively
license partners to develop the supplements for mass distribution
with the right fit larger and smaller organizations, including
pharmaceutical firms, biotech development firms, and
distribution/sales organizations. The Company has begun
negotiations in the United States and Canada and expects a great
revenue stream to help fuel the rest of its international drug
development and economic development programs.
About
Cannabis Science, Inc.
Cannabis
Science, Inc. takes advantage of its unique understanding of
metabolic processes to provide novel treatment approaches to a
number of illnesses for which current treatments and
understanding remain
unsatisfactory. Cannabinoids have an extensive history dating back
thousands of years, and currently, there are a growing number of
peer-reviewed scientific publications that document the underlying
biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, the characterization of
medicines, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on cancers, HIV/AIDS, and neurological
conditions. The Company is proceeding with the research and
development of its proprietary drugs as a part of this initial
focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1,
respectively.
Forward-Looking
Statements
This
Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements. Safe Harbor
Statement. The Private Securities Litigation Reform Act of 1995
provides a 'safe harbor' for forward looking statements. Certain of
the statements contained herein, which are not historical facts are
forward looking statements with respect to events, the occurrence
of which involved risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by
various factors. Information concerning potential factors that
could affect the company is detailed from time to time in the
company's reports filed with the Securities and Exchange
Commission.
Contact
Information
Cannabis Science,
Inc.
Mr.
Raymond C. Dabney
President
& CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel:
1-888-263-0832